Market Research Report
Myelodysplastic Syndrome - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||229721|
|Published||Content info||1542 Pages
Delivery time: 1-2 business days
|Myelodysplastic Syndrome - Pipeline Review, H2 2019|
|Published: December 16, 2019||Content info: 1542 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 84, 63, 2, 8, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 9, 4 and 3 molecules, respectively.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.